Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10052286 | 1.00 | L3MBTL1 (0.33) | L3MBTL1DPP4DPP8DPP9PIK3CD | |
| SCHEMBL23485120 | 1.00 | L3MBTL1 (0.33) | L3MBTL1DPP4DPP8DPP9PIK3CD | |
| SCHEMBL23488614 | 0.79 | L3MBTL1 (0.43) | L3MBTL1PIK3CD | |
| SCHEMBL9980259 | 0.76 | L3MBTL1 (0.38) | L3MBTL1DPP4DPP8DPP9MAPK1 | |
| SCHEMBL2757452 | 0.76 | MAPK1 (0.35) | DPP4DPP8DPP9PIK3CDMAPK1 | |
| SCHEMBL10052288 | 0.74 | — | — | |
| SCHEMBL2705993 | 0.74 | — | — | |
| SCHEMBL14558062 | 0.72 | MMP2 (0.36) | L3MBTL1DPP4DPP8DPP9 | |
| SCHEMBL21145968 | 0.71 | PIK3CD (0.33) | DPP4DPP8DPP9PIK3CD | |
| SCHEMBL15462354 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-8841278-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8273341-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | L3MBTL1 2200/4885DPP4 77/4885DPP8 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.